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Abstract
BACKGROUND: Diabetes mellitus (DM) is a metabolic disorder which may complicate other organs, including the 
nervous system. Literatures which discuss about DM complications in the peripheral nervous system are easy to find 
but not so many of the central nervous system. Central diabetic neuropathy is a new concept which could be detected 
by a simple and non-invasive method, called brainstem auditory evoked potential (BAEP).
AIM: The aim of the study was to find differences in BAEP latencies of a diabetic patient with good and poor glycemic 
control.
METHODS: This was a cross-sectional study of 80 patients who came for follow-up in diabetic center and neurology 
polyclinic at Sanglah Hospital, from April to July 2016. The subjects were divided into two groups, depending on their 
glycemic control, then having BAEP examination.
RESULTS: The unpaired t-test found prolonged BAEP latencies (either peak latency of wave III, V, IPL I-III, III-V, and 
I-V) in both ears at the poor glycemic control group, but the results were not differed significantly (p > 0.05).
CONCLUSION: BAEP wave latencies were found prolonged in DM patient with poor glycemic control but not 
statistically significant. Further evaluation of BAEP latencies in DM patients is needed with prolonged duration and 
their relation with other comorbid factors, especially smoking habit.
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Introduction
Diabetes mellitus (DM) is a common metabolic 
disorder. It may cause disability in many other organs, 
including the nervous system. This disorder rapidly 
becomes an epidemic in both developed and middle-
income countries. Associated with the nervous system 
itself, much of the literature mentioned DM complication 
in the peripheral nervous system, whereas the central 
nervous system (CNS) complication was less frequently 
studied. Some researchers recently show that diabetes 
may also cause neuropathy in CNS.
Diabetes prevalence has reached epidemic 
proportion. In January 2011, the national diabetic 
factsheet states there are about 246 million diabetics 
worldwide throughout 2010, with an incidence of 11.3% 
aged between 20 and 65 years [1]. The latest estimate 
from the International Diabetic Federation is 382 million 
people living with diabetes by 2013. In 2035, the amount 
is estimated to increase to 592 million people [2]. It 
was estimated that of 382 million people, 175 million of 
them had not appropriately diagnosed, which may have 
complication without proper prevention. The proportion 
of DM in Indonesia based on Riskesdas 2013 was 
6.9%. If the estimated population of Indonesian aged 
15 or more in 2013 is 176.689.336, then the estimated 
amount was about 12 million people with DM [3].
Prolonged hyperglycemia due to diabetes may 
cause complication to various body systems, including 
neuropathy [3]. Diabetic neuropathy obtained in nearly 
half of the diabetic population and result in higher 
morbidity and mortality. Poorly controlled blood sugar 
level (which reflected through HbA1C level in blood), 
duration of suffering DM, and other cardiovascular risk 
factors such as smoking and hypertension, are also 
become the risk of diabetic neuropathy [2].
Diabetic neuropathy complication can interfere 
with CNS as well. Some studies mention that diabetes 
is related with hearing impairment, and seems that good 
A1C level related with less frequent hearing loss in DM 
patient [4], [5], [6], [7]. This hearing function in CNS 
can be detected by a simple and non-invasive method 
which called brainstem auditory evoked potential 
(BAEP). This examination can detect abnormalities of 
the acoustic nerve function up to upper brainstem at an 
early stage by showing changes in wave latencies [8]. 
The amplitude of BAEP was often not taken into account 
because the variability is too high [9].
Standard BAEP results consist of seven 
waves. The first five waves were used in routine clinical 
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practice because of its consistency [10]. Wave I comes 
from the peripheral part of cranial nerve VIII (auditory 
nerve) near the cochlear nucleus. Wave II comes from 
the cochlear nucleus, wave III of the superior oliva 
nucleus, wave IV of the lateral lemniscus, and wave 
V of the inferior colliculus in mesencephalon [11]. 
Central diabetic neuropathy of auditory pathways in 
the brainstem may cause hearing loss. Many sufferers 
do not realize that they have suffered from hearing 
loss due to the disease’s slow progression. Therefore, 
clinicians need to monitor hearing function in patients 
with DM, in addition to other routine evaluation of DM 
complication so that early intervention can be provided 
if necessary [11].
Some studies of BAEP abnormalities in 
patients with DM have been done in various places 
around the world, but the results vary [12]. Research 
by Li et al. (2005) found that latency wave BAEP, for 
example, wave III and V and interpeak latency (IPL) I-III 
and III-V was prolonged in patients with DM compared 
with healthy individuals [13].
According to Abo-Elfetoh et al. (2015), patients 
with poor glycemic control had prolonged absolute 
BAEP latency which is significant from wave I with 
the extension followed by wave latency III and V; 
also IPL III-V compared to the control group (healthy 
individuals) [14]. This may indicate the involvement 
of both peripheral and central auditory pathways. The 
study by Bayazit et al., 2000, was also consistent with 
other studies using BAEP [15], [16], which found the 
elongation of wave latency III and V. However, there 
were some researches, [17], [18] León-Morales et al. 
and Talebi et al. reported that there was no correlation 
between HbA1C levels and BAEP results.
Data related to the effect of HbA1c levels 
on hearing function in patients with DM are still a 
controversy. Some research does not even show that 
poor blood sugar control harms hearing function [19] 
other than that, not much data have been obtained 
regarding BAEP abnormalities in DM patients at 
Indonesia.
The American Diabetes Association and other 
organizations, which define the target concentration of 
HbA1C as the target of optimal blood sugar control [20]. 
The 2015 Indonesian Endocrine Associates Consensus 
recommends the main objective of DM therapy is the 
value of HbA1c <7% [21].
Until now, various studies that perform BAEP 
examination in patients with DM used a healthy individual 
as control [9], [14], [16], [18], [22], [23], [24], while in this 
study we compare BAEP results in patients with DM only.
As far as, our knowledge, in Bali, there is no 
research yet using BAEP to assess the possibility of 
central diabetic neuropathy in the auditory system of DM 
patients. The purpose of the study is to find differences 
in BAEP latencies of a diabetic patient with good and 
poor glycemic control.
Materials and Methods
Based on the statistical calculation, minimal 
sample required was 40 subjects of each group. 
Subjects of this study were collected with consecutive 
random sampling. All subjects who meet eligibility 
were taken as a sample until the required amount was 
complete. This is a cross-sectional study of patients who 
came for follow-up in Diabetic Center and Neurology 
polyclinic at Sanglah Hospital, from April to July 2016. 
The subjects were divided into two groups, depending 
on their glycemic control by assessing HbA1C level 
within the past 3 months, before both ears BAEP.
Inclusion criteria
The following criteria were included in the 
study:
•	 DM patient with good glycemic control (HbA1C 
<7%) or poor glycemic control (HbA1C≥7%)
•	 Age between 40 and 65 years old
•	 Patients were fully alert, evaluated with the 
Glasgow Coma scale, and willing to join this 
study by sign in the consent form.
Exclusion criteria
The following criteria were excluded from the 
study:
•	 Having diabetics for more than 10 years
•	 The patient who is on acute ENT inflammation
•	 Patient with a chronic media ear infection 
or other ear illness which cause permanent 
hearing loss
•	 Malignancy of ENT area
•	 History of ototoxic medicines consumption 
continuously more than 3 months
•	 Noise working environment or living area
•	 History of having high explosion sound near 
both ears
•	 History of HIV infection, chronic kidney disease, 
and multiple sclerosis.
Subject characteristics were taken from the 
interview and medical records. Physical examination 
of outer ear by otoscope and hearing function was 
evaluated by tuning fork 256 Hz. The BAEP latencies 
were done by EMG/EP Keypoint Dantec machine, 
made in Denmark 2015. The BAEP wave recorded with 
headphone, click sound stimulus, with duration 0.1 ms, 
stimulus frequency 10 Hz, averaging 2000, and stimulus 
intensity 90 dB. The active electrode was placed at both 
mastoid bones; the ground electrode was in the middle of 
the frontal bone (Fpz). Normal value was as mentioned 
by the machine standard in milliseconds (ms). Normal 
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peak latency of wave I: 2 ms; wave III: 4.28 ms; and 
wave V: 6.2 ms. The normal value for IPL I-III: 2.4 ms; 
IPL III-V: 2.26 ms; and IPL I-V: 4.46 ms. Glycemic control 
measurement using HbA1c level, which evaluated 
within the last 3 months. The HbA1c level was checked 
with turbidimetry method by an automatic autoanalyzer 
(Cobas Integra 400 Plus analyzer from Roche). Diabetic 
patient with good and poor glycemic control was the 
independent variable, while BAEP latencies were the 
dependent variable. Duration of diabetic, dyslipidemia, 
hypertension, and smoking history were acted as bias. 
All collected data were then statistically analyzed with 
SPSS 17.0 for windows.
Results
The unpaired t-test found prolonged persistent 
BAEP latencies (either peak latency of wave III, V, IPL 
I-III, III-V, and I-V) in both ears at the poor glycemic control 
group, but the results were not differed significantly (p > 
0.05). However, there was significant difference of BAEP 
latency base on duration of DM group and cigarettes 
consumption group, as shown in Table 1.
Table 1: Basic characteristics of research subject
Variable Good glycemic 
control (n=40) n (%)
Poor glycemic 
control (n=40) n (%)
p
Age mean (years) 54±5.292 53±7.491 0.219
HbA1c 6.155±0.665 8.992±1.504 0.001*
Gender
Male 26 (65) 26 (65) 1.000
Female 14 (35) 14 (35)
Education level
No school 5 (12.5) 2 (5) 0.127
Elementary school 6 (15) 5 (12.5)
Junior high school 3 (7.5) 2 (5)
Senior high school 12 (30) 11 (27.5)
University 14 (35) 20 (50)
Job
Farmer/laborers 4 (10) 2 (5) 0.102
Entrepreneur 10 (25) 9 (22.5)
Private employee 6 (15) 8 (20)
Government employee 9 (22.5) 14 (35)
Others 11 (27.5) 7 (17.5)
Duration of DM (years)
<5 30 (75) 17 (42.5) 0.003*
5–10 10 (25) 23 (57.5)
Hypertension
Yes 14 (35) 9 (22.5) 0.220
No 26 (65) 31 (77.5)
Dyslipidemia
Yes 16 (40) 22 (55) 0.182
No 24 (60) 18 (45)
Hearing loss
Yes 6 (15) 7 (17.5) 0.763
No 34 (85) 33 (82.5)
Tuning fork test
SNHL 3 (7.5) 7 (17.5) 0.179
Normal 37 (92.5) 33 (82.5)
Smoking
Yes 6 (15) 11 (27.5) 0.174
No 34 (85) 29 (72.5)
DM medication
Insulin 18 (45) 31 (77.5) 0.021*
Oral antidiabetic 22 (55) 4 (10)
Insulin+oral medicine 0 5 (12.5)
*Statistically significant.
Bivariate analysis of BAEP latency with 
glycemic control in DM patients
The latency of wave III, V, IPL I-III, III-V, and 
I-V (measured at 90 dB intensity) from both ears 
is tested for normality with Kolmogorov–Smirnov, 
showing normal scattered data except in the right and 
left IPL III-V. Hypothesis test used is unpaired t-test (in 
normally distributed data), and Mann–Whitney test (on 
non-distributed data), significance level measured with 
p < 0.05. BAEP latency analysis results in each ear are 
presented in Table 2.
Table 2: The unpaired t-test bivariate analyzes of BAEP mean 
latency in the good and poor glycemic control group
Ear stimulation 
site
Wave Good glycemic 
control (n=40)
Poor glycemic 
control (n=40)
p
Left Latency III 4.080 ± 0.260 4.098 ± 0.284 0.775
Ear Latency V 6.023 ± 0.429 6.333 ± 0.402 0.166
IPL I-III 2.520 ± 0.318 2.530 ± 0.355 0.895
IPL III-V 2.098 ± 0.468 2.288 ± 0.662 0.145
IPL I-V 4.643 ± 0.459 4.688 ± 0.532 0.686
Right Latency III 4.013 ± 0.351 4.075 ± 0.298 0.393
Ear Latency V 6.025 ± 0.439 6.338 ± 0.384 0.155
IPL I-III 2.495 ± 0.410 2.544 ± 0.342 0.561
IPL III-V 2.192 ± 0.471 2.303 ± 0.618 0.646
IPL I-V 4.688 ± 0.546 4.755 ± 0.496 0.564
The results of statistical analysis from the data above indicate persistent prolonged BAEP wave latency 
either in wave latency III, V, IPL I-III, III-V, and IPL I-V, in both ears (p>0.05).
Statistical analysis of other factors 
possibly influences the difference between BAEP 
prolonged latency in diabetic patients
Other factors that may also affect the difference 
in BAEP latency in patients with DM are duration 
suffering from DM, hypertension, dyslipidemia, and 
cigarette consumption. The relationship between the 
four variables was analyzed by unpaired t-test. Mean 
value is set at probability value p < 0.05.
In this study, statistical analysis of BAEP 
latency shows no significant difference related to 
hypertension and dyslipidemia. Our subjects were then 
divided into two groups based on the duration of DM, 
i.e., less than 5 years and groups of 5–10 years. The 
result of the different analysis of BAEP latency average 
is shown in Table 3.
Table 3: The unpaired t-test bivariate analyzes of BAEP mean 
latency based on DM duration group
Ear stimulation 
site
Wave Duration <5 years Duration 5–10 years p
Left Latency III 4.043 ± 0.303 4.155 ± 0.205 0.068
Ear Latency V 6.153 ± 0.401 6.430 ± 0.393 0.003*
IPL I-III 2.481 ± 0.369 2.588 ± 0.272 0.160
IPL III-V 2.100 ± 0.387 2.324 ± 0.706 0.087
IPL I-V 4.581 ± 0.445 4.785 ± 0.541 0.069
Right Latency III 3.979 ± 0.329 4.136 ± 0.299 0.032*
Ear Latency V 6.191 ± 0.456 6.385 ± 0.323 0.040*
IPL I-III 2.470 ± 0.370 2.591 ± 0.378 0.156
IPL III-V 2.209 ± 0.503 2.303 ± 0.612 0.452
IPL I-V 4.677 ± 0.536 4.785 ± 0.541 0.362
*Statistically significant.
Based on the data in the table, there are 
significant latency differences in latency V left ear 
(p = 0.003), latency III (p = 0.032), and latency V 
(p = 0.040) of right ear. Another BAEP latency was also 
found to be consistently longer in both ears in the group 
with DM 5–10 years duration, but statistically, there 
were no significant difference.
Cigarettes are thought to affect the latency 
of BAEP in DM patients. In this study, the subjects 
were divided into two groups, namely, smokers and 
non-smokers. Individuals are said to be smokers when 
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they meet the criteria of smoking history = 10 cigarettes/
days for more than 1 year regularly [25]. In this study, 
no data obtained detail on how long the subject had 
been smoking before it stopped. Our data also do not 
include passive smoking conditions. The statistical 
analysis result of BAEP latency on diabetic smoker and 
non-smoker group is listed in Table 4.
Table 4: The unpaired t-test bivariate analyzes of BAEP mean 
latency based on smoker and non-smoker group
Ear stimulation 
site
Wave Smoker Non-smoker p
Left Latency III 3.944 ± 0.334 4.114 ± 0.248 0.105
Ear Latency V 6.294 ± 0.439 6.260 ± 0.416 0.770
IPL I-III 2.500 ± 0.302 2.532 ± 0.345 0.731
IPL III-V 2.453 ± 0.855 2.122 ± 0.462 0.035*
IPL I-V 4.647 ± 0.612 4.670 ± 0.463 0.867
Right Latency III 3.994 ± 0.327 4.057 ± 0.326 0.481
Ear Latency V 6.371 ± 0.348 6.244 ± 0.431 0.269
IPL I-III 2.447 ± 0.322 2.539 ± 0.389 0.373
IPL III-V 2.482 ± 0.754 2.184 ± 0.467 0.046*
IPL I-V 4.718 ± 0.514 4.722 ± 0.524 0.975
*Statistically significant
The data in Table 4 show that IPL III-V left and 
right ear were longer in the smokers’ group (p < 0.05).
Discussion
The age of our subjects was limited from 40 
to 65 years old. This was done to obtain the uniformity 
of the sample variant and to reduce the likelihood of 
bias on BAEP results due to presbycusis that possibly 
occurs in individuals over 65 years old [26]. The mean 
age of the two groups did not differ significantly with 
p = 0.219 (p > 0.05). The mean age is similar to study 
from Talebi et al. [18].
Based on sex, there were 52 male subjects 
(65%) and 14 female (35%) spread evenly in each 
group. Uniformity of the sample by sex in both groups 
got by chance. Similar previous studies have also 
gained men more than women [1], [9], [27].
Most of the study subjects suffered from DM 
with duration of fewer than 5 years (58.75%) while 
subjects who suffered from DM for 5–10 years as much 
as 41.25%. The same period was also used in previous 
studies [9], [14]. Most of the research similar take samples 
of DM patients with the duration of the disease more than 
10 years [8], [11], [16], [18], while Gupta et al. (2010) use 
the duration range suffered DM less than 5 years in the 
sample research [27]. Research subjects in both groups 
more non-smoker (78.8%) than smoker (21.3%).
BAEP latency differences in diabetic 
patients with good and poor glycemic control
BAEP was examined in both groups after 
being classified depends on their glycemic control 
(by assessing the HbA1c level). The examination 
performed with “click” sound stimulus provided through 
headphones, with 90 dB intensity. Patients lying supine, 
having paired active electrode placed in both mastoid 
bones (A1 and A2), and the reference electrode was 
placed in Cz and ground electrode in Fpz. BAEP wave 
was recorded twice in each ear to ensure uniformity 
of the wave generated. This examination method was 
similar to other earlier studies [9], [14], [18].
Some previous studies which evaluated BAEP 
latency in DM patients obtained that latency of wave 
I was no different in a group of DM patient compare 
with healthy person group [11], [27]. Our research only 
evaluated BAEP latency of wave III, V, IPL I-III, III-V, 
and I-V from both ears.
Most studies which evaluate BAEP latency 
in DM patients compare its results with a healthy 
control group and are found to be significantly 
differed [12], [18], [22]. In this study, both groups were 
people with DM.
As a final result, in this study, we find 
consistently prolonged BAEP latency on poor glycemic 
control group of both ears at the latency of wave III, 
V, IPL I-III, III-V, and IPL I-V compare than the good 
glycemic control group. However, the BAEP wave 
latency was not statistically significant (p > 0.05) in both 
groups.
The results of this study are similar to the 
previous studies [10], [17], [18]. Those researches also 
showed no significant correlation between HbA1c levels 
with BAEP latency. A study by Abdulkadiroglu et al. 
(1999) also found no correlation between the extension 
of latency BAEP and glycemic control [9].
Mahalik et al. (2014) conducted a study 
comparing patients with good glycemic control Type 
2 DM, compared with healthy people. The analysis 
result shows that there was an extension of wave III 
latency on DM patients compared to the control group 
(p = 0.001), but no significant difference in wave latency 
V (p = 0.16). It also obtained significant IPL extension 
between-group diabetics compared to the healthy 
control group.
Our study differ from that of Abo-Elfetoh et al. 
(2015) who compared three groups of samples, i.e., 
DM patient with good and poor glycemic control and 
healthy individuals. BAEP examination is done with the 
same intensity as our study. This study found significant 
latency elongation of the waves V, IPL I-III, and III-V in 
poor glycemic control group [14], [23]. However, this 
study includes samples with age range of 32–70 years 
old. It may play an important role because of presbycusis 
events increased sharply over the age of 65 years [26].
The difference in BAEP latency based on 
DM duration
In our study, subjects were divided into two 
groups based on the length of DM, i.e., <5 years 
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and between 5 and 10 years. Based on the result of 
statistical data analysis with unpaired t-test, there is a 
significant difference of BAEP latency on wave III right 
ear (p = 0,032), wave V left and right ear (p = 0.003 and 
0.040, respectively).
This result is similar to other studies [9], [15]. 
In both studies, it was concluded that central and 
peripheral neuropathy in DM was related to the duration 
of illness and is not associated with blood sugar levels 
and metabolic control. It was concluded that the 
duration of diabetes is a definitive risk factor for the 
occurrence of central diabetic neuropathy [15], [27]. 
Study by Shatdal et al. (2013) also found significant 
IPL III-V elongation in DM patients whom diagnosed for 
more than 5 years [10].
Our study has a different result to Takkar et al. 
(2013) which found there was no statistically significant 
difference related to duration suffers from DM, due to 
well controlled blood sugar [8].
BAEP latency differences in DM smokers 
and non-smokers
In this study, we also want to know whether 
cigarettes consumption has affect BAEP latency in 
DM patient. Statistical analysis shows a significant 
difference in BAEP latency (p < 0.05) among smoking 
groups compared with the non-smoking.
Heavy smokers (more than 20 cigarettes 
per day) are reported to have a higher risk of insulin 
resistance, up to 61%, while less frequent smokers 
(<20 cigarettes per day) were associated with a 29% 
risk. Former smokers have a risk of only 23% higher. 
Mitochondrial dysfunction, oxidative stress, and 
inflammation are some mechanism involved in the 
underlying nicotine-induced nerve toxicity [28]. There 
are also research data which states that DM patients 
who are active smoker had a 14-fold risk of developing 
DM complications compared with patients with DM 
alone or smokers only [29].
Smoking and nicotine consumption will raise 
hormone levels in such to circulating catecholamines, 
glucagon, and growth hormone, which can interfere 
with work insulin. From the research was concluded that 
nicotine especially could cause damage to people who 
have a fragile prior health condition health, for example, 
patients with DM [30]. This explanation can be a reason 
why in our study we found significantly elongation of 
BAEP latency in DM patient who smokes (p < 0.05).
Conclusion
Based on the results of this study, it was 
concluded that BAEP wave latency consistently longer 
in the group of diabetic patients with poor glycemic 
control (p > 0.05). Our study also found significant 
prolonged BAEP wave latency related to DM duration 
and in DM patient group who was smoker (p < 0.05).
Suggestion
Some suggestions based from our study 
results are:
1. BAEP can be used as an early screening 
in DM patients for the possibility of central 
neuropathy diabetic. More awareness should 
be given to DM patient with poor glycemic 
control, smoker and has been suffering DM for 
more than 5 years
2. It is best to give proper education about the 
importance of glycemic control and routine 
evaluation regarding possible complications of 
DM
3. Need to do further research with the longer 
duration of DM (>10 years) to see whether 
longer DM duration will significantly affect 
BAEP latency. Further research on DM patients 
can also be completed by screening for central 
diabetic neuropathy compared with peripheral 
nerve conduction examination. Expected to 
get data whether central diabetic neuropathy 
occurred after, before, or simultaneously with 
peripheral neuropathy.
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